Hemogenyx CEO, Vladislav Sandler, Explains the Near-Term Revenue Opportunity from CAR-T in Estonia

Hemogenyx Pharmaceuticals (LSE:HEMO) is progressing toward its first revenue opportunity foe CAR-T therapy for relapsed/refractory acute myeloid leukemia. CEO & Co-Founder, Vladislav Sandler, explains how a new Estonian hospital exemption law could generate early revenue for the Company before full commercialisation, through government reimbursement and international patients. In this interview, investors will learn: - How Hemogenyx plans to monetize CAR-T ahead of full approval - Why Estonian law and CELIN Technologies are fast-tracking access - When near-term revenue potential from both domestic and international patients can be expected - How HEMO will be collecting real-world data for future patient selection - What the funding strategy, burn-rate reduction, and pipeline now looks like beyond CAR-T Vladislav Sandler, CEO at Hemogenyx Pharmaceuticals , was interviewed by Sarah Lowther for focusIR.